| abstract |
Compounds of formula (I): n nwherein n X is O, CH 2 , S or NH, or the moiety X—R 1 is hydrogen; V is CH or N; R 1 is hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, aryl, arylC 1-6 alkyl, heterocyclyl, heterocyclylC 1-6 alkyl, heteroaryl, or heteroarylC 1-6 alkyl any of which except for hydrogen may be optionally substituted; R 2 and R 3 independently represent optionally substituted C 1-6 alkyl, or R 2 and R 3 together with the carbon atom to which they are attached form an optionally substituted C 3-7 cycloalkyl or C 3-7 cycloalkenyl ring; or R 2 and R 3 together with the carbon atom to which they are attached form an optionally substituted 5 to 7-membered heterocyclyl ring containing up to 3 heteroatoms selected from N, O, S.R 4 and R 5 independently represent hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, aryl, arylC 1-6 alkyl, heteroaryl, heteroarylC 1-6 alkyl, heterocyclyl, or heterocyclylC 1-6 alkyl, any of which except for hydrogen may be optionally substituted or R 4 and R 5 together with the nitrogen atom to which they are attached form 4- to 8-membered ring; Ar is an aryl or heteroaryl ring either of which may be optionally substituted; one of X 1 and X 2 is N and the other is NR 6 , wherein R 6 is hydrogen, C 1-6 alkyl, or arylC 1-6 alkyl or pharmaceutically acceptable salts thereof, their use as inhibitors of Raf kinases, and pharmaceutical compositions containing them. |